BRICKELL BIOTECH INC (BBI) Stock Price, Forecast & Analysis
USA - NASDAQ:BBI - US10802T2042 - Common Stock
BBI Key Statistics, Chart & Performance
The current stock price of BBI is 2.35 USD. In the past month the price decreased by -35.26%. In the past year, price decreased by -93.39%.
BBI Latest News, Press Relases and Analysis
BBI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About BBI
Company Profile
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
Company Info
BRICKELL BIOTECH INC
5777 Central Ave Ste 102
Boulder COLORADO 80301 US
CEO: Robert B. Brown
Employees: 16
Phone: 17205054755.0
BRICKELL BIOTECH INC / BBI FAQ
Can you describe the business of BRICKELL BIOTECH INC?
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
What is the stock price of BRICKELL BIOTECH INC today?
The current stock price of BBI is 2.35 USD. The price increased by 2.17% in the last trading session.
Does BRICKELL BIOTECH INC pay dividends?
BBI does not pay a dividend.
What is the ChartMill rating of BRICKELL BIOTECH INC stock?
BBI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting BBI stock to perform?
8 analysts have analysed BBI and the average price target is 18.19 USD. This implies a price increase of 674.04% is expected in the next year compared to the current price of 2.35.
Can you provide the growth outlook for BRICKELL BIOTECH INC?
The Revenue of BRICKELL BIOTECH INC (BBI) is expected to grow by 1253.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for BBI stock?
You can find the ownership structure of BRICKELL BIOTECH INC (BBI) on the Ownership tab.
BBI Technical Analysis
BBI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBI. Both the profitability and financial health of BBI have multiple concerns.
BBI Financial Highlights
Over the last trailing twelve months BBI reported a non-GAAP Earnings per Share(EPS) of -20.7. The EPS decreased by -1880.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8325.47% | ||
| ROA | -191.83% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BBI Forecast & Estimates
8 analysts have analysed BBI and the average price target is 18.19 USD. This implies a price increase of 674.04% is expected in the next year compared to the current price of 2.35.
For the next year, analysts expect an EPS growth of 70.65% and a revenue growth 1253.05% for BBI